ACR Encourages Safe Adoption of Biosimilars

ACR Encourages Safe Adoption of Biosimilars

During a recent public meeting held by the FDA's Arthritis Advisory Committee to review the license application for CT-P13 (Celltrion), a proposed biosimilar to Remicade (infliximab, Janssen Biotech), the American College of Rheumatology (ACR) provided

(Visited 1 times, 1 visits today)
1
Like
Save

Comments

Comments are disabled for this post.